June 4, 2012 – Two recent studies appear to confirm a mountain of previous evidence indicating a link between Takeda’s blockbuster diabetes drug Actos (generic: pioglitazone) and bladder cancer. The research, which was published last week in the British Medical Journal, found that Actos may double the risk of bladder cancer after two years, supporting recent warnings added to the drug’s label regarding the risks associated with long-term use. First approved by the U.S. Food & Drug Administration (FDA) in July 1999, Actos is a once-daily diabetes medication that is designed to increase the body’s sensitivity to insulin.
Actos Bladder Cancer Lawsuit Update April 8, 2014: In the first U.S. trial of its kind, Takeda Pharmaceuticals and Eli Lilly were ordered to pay a total of $9 billion in punitive damages after a jury agreed that the companies failed to warn the public and medical communities about the bladder cancer risk associated with their controversial type 2 diabetes drug Actos (pioglitazone). The lawsuit claimed that Takeda and Lilly downplayed or ignored concerns about Actos’ link to bladder cancer, and mislead health authorities in order to protect profits. Click here to learn more.
Free Actos Bladder Cancer Lawsuit Evaluation: If you or a loved one has been diagnosed with bladder cancer after taking Actos, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against the manufacturer of Actos and we can help.
What’s the problem?
For one study, Canadian researchers examined data on more than 115,000 patients who took diabetes medications from 1988 to 2009. They found that not only did the bladder cancer risk increase the longer the individual was treated with Actos, but that the risk seemed to be dose specific and increasing in proportion to the dose taken. Additional research presented at last month’s American Society of Clinical Oncology’s annual meeting indicated that the risk of bladder cancer may apply not only to Actos, but to all drugs in the same class known as glitazones or thiazolidinediones.
In addition to Actos, other medications belonging to this class include:
Researchers from the University of Pennsylvania analyzed the medical records of approximately 60,000 patients who took glitazones for extended periods of time, and found that after five years, the test subjects were at a 72% increased risk of developing bladder cancer. The study also found that all drugs from the glitazone class equally increased the risk of bladder cancer.
Actos is the only glitazone still widely available in the United States. Rezulin was recalled in 2000 due to a risk of liver damage, and Avandia was slapped with severe restrictions last year due to an increased risk of heart attacks.
Over the past year and a half, Actos has been repeatedly linked to bladder cancer, resulting in updated warning labels in the United States, Europe and Canada. A growing movement within the medical community is calling for a nationwide Actos recall, and French health regulators pulled the drug off the market in that country last June.
A growing number of Actos lawsuits are being filed against Takeda in courthouses around the country on behalf of individuals who allegedly developed bladder cancer after taking the drug. The suits claim that Takeda failed to adequately research Actos prior to releasing it on to the market, or warn the public about the drug’s potential to cause bladder cancer.
Do I Have an Actos Bladder Cancer Lawsuit?
The Product Liability & Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Actos lawsuits. We are handling individual litigation nationwide and currently accepting new bladder cancer cases in all 50 states.
Free Actos Bladder Cancer Lawsuit Evaluation: If you or a loved one has been diagnosed with bladder cancer after taking Actos, you should contact our law firm immediately. You may be entitled to compensation by filing an Actos bladder cancer suit and we can help.